comparemela.com

Latest Breaking News On - Formosa pharmaceuticals - Page 9 : comparemela.com

Corcept terminates Phase III pancreatic ductal adenocarcinoma trial

Apart from pancreatic ductal adenocarcinoma, studies in liver disease, venous leg ulcer, sleep apnoea, and ocular issues are also reviewed.

Mediwound escharexCentric services forLaboratory equipmentDrug processing technologyFormosa pharmaceuticalsPipeline movesCorcept therapeuticsTrials arenaPhase transition success rateProcessing technologyPreference management solutionCentric servicesAlternate site clinical trials

Taiwan strengthens treatment offering for inflammation and pain after cataract surgery

Formosa Pharmaceuticals and AimMax Therapeutics announced positive results of ophthalmic drug

United statesMerick coFormosa pharmaceuticalsTaiwan based formosa pharmaceuticalsAimmax therapeuticsFormosa pharmaceutical chief executiveOphthalmic drugFormosa pharmaceuticalsAimmax therapeuticsClinical trials

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

/PRNewswire/ Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the.

United statesNorth carolinaResearch triangle parkAimmax therapeutics incFormosa pharmaceuticalsAimmax therapeuticsMax therapeuticsFormosa pharmaceuticals inc

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

/PRNewswire/ Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of.

United statesNorth carolinaResearch triangle parkJeffrey levensonAimmax therapeutics incFormosa pharmaceuticals incFormosa pharmaceuticalsClobetasol propionate ophthalmic nanosuspensionCataract surgeryFormosa pharmaceuticalAimmax therapeuticsMax therapeuticsPharmaceuticals incFormosa pharmaceuticals inc

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

/PRNewswire/ Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of.

United statesNorth carolinaResearch triangle parkJeffrey levensonAimmax therapeutics incFormosa pharmaceuticals incFormosa pharmaceuticalsClobetasol propionate ophthalmic nanosuspensionCataract surgeryFormosa pharmaceuticalAimmax therapeuticsMax therapeuticsPharmaceuticals inc

vimarsana © 2020. All Rights Reserved.